Display options
Share it on

Oncol Lett. 2017 Mar;13(3):1137-1142. doi: 10.3892/ol.2016.5535. Epub 2016 Dec 27.

JS-K promotes apoptosis by inducing ROS production in human prostate cancer cells.

Oncology letters

Mingning Qiu, Lieqian Chen, Guobin Tan, Longzhi Ke, Sai Zhang, Hege Chen, Jianjun Liu

Affiliations

  1. Laboratory of Urology, Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China.

PMID: 28454225 PMCID: PMC5403315 DOI: 10.3892/ol.2016.5535

Abstract

Reactive oxygen species (ROS) are chemical species that alter redox status, and are responsible for inducing carcinogenesis. The purpose of the present study was to assess the effects of the glutathione S transferase-activated nitric oxide donor prodrug, JS-K, on ROS accumulation and on proliferation and apoptosis in human prostate cancer cells. Cell proliferation and apoptosis, ROS accumulation and the activation of the mitochondrial signaling pathway were measured. The results demonstrated that JS-K may inhibit prostate cancer cell growth in a dose- and time-dependent manner, and induce ROS accumulation and apoptosis in a dose-dependent manner. With increasing concentrations of JS-K, expression of pro-apoptotic proteins increased, but Bcl-2 expression decreased. Additionally, the antioxidant N-acetylcysteine reversed JS-K-induced cell apoptosis; conversely, the pro-oxidant glutathione disulfide exacerbated JS-K-induced apoptosis. In conclusion, the data suggest that JS-K induces prostate cancer cell apoptosis by increasing ROS levels.

Keywords: JS-K; apoptosis; nitric oxide; prostate cancer cells; reactive oxygen species

References

  1. J Biomed Sci. 2014 Jan 13;21:3 - PubMed
  2. Mol Cancer Ther. 2003 Apr;2(4):409-17 - PubMed
  3. Cell Signal. 2012 May;24(5):981-90 - PubMed
  4. Trends Biochem Sci. 1997 Aug;22(8):299-306 - PubMed
  5. Am J Hum Genet. 1999 May;64(5):1282-8 - PubMed
  6. Mol Carcinog. 2014 Jul;53(7):537-47 - PubMed
  7. Blood. 2007 Jul 15;110(2):709-18 - PubMed
  8. Anticancer Drugs. 2006 Apr;17(4):471-8 - PubMed
  9. BMC Cancer. 2012 Mar 30;12:130 - PubMed
  10. Cancer Metastasis Rev. 2006 Dec;25(4):695-705 - PubMed
  11. Nature. 1992 Mar 26;356(6367):356-8 - PubMed
  12. FEBS J. 2009 Nov;276(21):6063-73 - PubMed
  13. J Pharmacol Exp Ther. 2011 Feb;336(2):313-20 - PubMed
  14. Evid Based Complement Alternat Med. 2012;2012:765316 - PubMed
  15. Toxicology. 2009 Jun 16;260(1-3):60-7 - PubMed

Publication Types